272 related articles for article (PubMed ID: 35105345)
1. Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.
Oudaert I; Satilmis H; Vlummens P; De Brouwer W; Maes A; Hose D; De Bruyne E; Ghesquière B; Vanderkerken K; De Veirman K; Menu E
J Exp Clin Cancer Res; 2022 Feb; 41(1):45. PubMed ID: 35105345
[TBL] [Abstract][Full Text] [Related]
2. PYCR in Kidney Renal Papillary Cell Carcinoma: Expression, Prognosis, Gene Regulation Network, and Regulation Targets.
Shao Z; Lu L; Cui Y; Deng L; Xu Q; Liang Q; Lu X; Zhang J; Chen J; Situ Y
Front Biosci (Landmark Ed); 2022 Dec; 27(12):336. PubMed ID: 36624948
[TBL] [Abstract][Full Text] [Related]
3. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y
Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297
[TBL] [Abstract][Full Text] [Related]
4. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
5. A fragment-like approach to PYCR1 inhibition.
Milne K; Sun J; Zaal EA; Mowat J; Celie PHN; Fish A; Berkers CR; Forlani G; Loayza-Puch F; Jamieson C; Agami R
Bioorg Med Chem Lett; 2019 Sep; 29(18):2626-2631. PubMed ID: 31362921
[TBL] [Abstract][Full Text] [Related]
6. Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells.
Zhang J; Shang L; Jiang W; Wu W
Bioengineered; 2022 Mar; 13(3):7904-7918. PubMed ID: 35293266
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of Pycr1 and Pycr2 in mice.
Stum MG; Tadenev ALD; Seburn KL; Miers KE; Poon PP; McMaster CR; Robinson C; Kane C; Silva KA; Cliften PF; Sundberg JP; Reinholdt LG; John SWM; Burgess RW
Genetics; 2021 May; 218(1):. PubMed ID: 33734376
[TBL] [Abstract][Full Text] [Related]
8. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
9. Pyrroline-5-carboxylate reductase 1 (PYCR1) upregulation contributes to gastric cancer progression and indicates poor survival outcome.
Xiao S; Li S; Yuan Z; Zhou L
Ann Transl Med; 2020 Aug; 8(15):937. PubMed ID: 32953737
[TBL] [Abstract][Full Text] [Related]
10. Pyrroline-5-carboxylate reductase 1 promotes cell proliferation via inhibiting apoptosis in human malignant melanoma.
Ye Y; Wu Y; Wang J
Cancer Manag Res; 2018; 10():6399-6407. PubMed ID: 30568501
[TBL] [Abstract][Full Text] [Related]
11. PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer.
Zhuang J; Song Y; Ye Y; He S; Ma X; Zhang M; Ni J; Wang J; Xia W
J Transl Med; 2019 Oct; 17(1):343. PubMed ID: 31619254
[TBL] [Abstract][Full Text] [Related]
12. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
13. Resolving the cofactor-binding site in the proline biosynthetic enzyme human pyrroline-5-carboxylate reductase 1.
Christensen EM; Patel SM; Korasick DA; Campbell AC; Krause KL; Becker DF; Tanner JJ
J Biol Chem; 2017 Apr; 292(17):7233-7243. PubMed ID: 28258219
[TBL] [Abstract][Full Text] [Related]
14. Structure, biochemistry, and gene expression patterns of the proline biosynthetic enzyme pyrroline-5-carboxylate reductase (PYCR), an emerging cancer therapy target.
Bogner AN; Stiers KM; Tanner JJ
Amino Acids; 2021 Dec; 53(12):1817-1834. PubMed ID: 34003320
[TBL] [Abstract][Full Text] [Related]
15.
Christensen EM; Bogner AN; Vandekeere A; Tam GS; Patel SM; Becker DF; Fendt SM; Tanner JJ
J Biol Chem; 2020 Dec; 295(52):18316-18327. PubMed ID: 33109600
[TBL] [Abstract][Full Text] [Related]
16. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
[TBL] [Abstract][Full Text] [Related]
17. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27.
Li J; Zhang X; Shen J; Guo J; Wang X; Liu J
Mol Med Rep; 2019 Sep; 20(3):2410-2418. PubMed ID: 31322176
[TBL] [Abstract][Full Text] [Related]
19. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.
Xu B; Li J; Xu D; Ran Q
Ir J Med Sci; 2023 Apr; 192(2):561-567. PubMed ID: 35508865
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
